VCs back start-up in £96M series A, joining AGTC takeout with pair of preclinical programs

Data for X-linked retinitis pigmentosa, geographic atrophy support moving into later-stage trials

For one of two gene therapy programs Biogen acquired in its takeout of Nightstar, the future is in doubt following its failure to meet the primary endpoint in a Phase II/III trial to treat X-linked

How gene therapy manufacturing bottlenecks are impeding academic translation

What Biogen is building in neurology